PhaseBio Pharmaceuticals, Inc.

Equities

PHAS.Q

US7172241090

Biotechnology & Medical Research

End-of-day quote OTC Markets Other stock markets 18:00:00 2024-05-20 EDT			5-day change	1st Jan Change
0.000001 ^USD	0.00%		0.00%	0.00%

05-13	Amended Disclosure Statement Conditionally Approved for PhaseBio Pharmaceuticals, Inc.	CI
04-19	First Amended Combined Liquidation Plan and Disclousre Statement Filed by PhaseBio Pharmaceuticals, Inc.	CI

PhaseBio Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021

November 10, 2021 at 04:39 pm

PhaseBio Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported revenue was USD 0.335 million. Net loss was USD 31.92 million compared to USD 25.14 million a year ago. Basic loss per share from continuing operations was USD 0.66 compared to USD 0.86 a year ago. For the nine months, revenue was USD 10.67 million compared to USD 0.32 million a year ago. Net loss was USD 87.96 million compared to USD 68.19 million a year ago. Basic loss per share from continuing operations was USD 2.07 compared to USD 2.36 a year ago.

Latest news about PhaseBio Pharmaceuticals, Inc.

Amended Disclosure Statement Conditionally Approved for PhaseBio Pharmaceuticals, Inc.	05-13	CI
First Amended Combined Liquidation Plan and Disclousre Statement Filed by PhaseBio Pharmaceuticals, Inc.	04-19	CI
Fifth Motion for Exclusivity Period Extension Approved For PhaseBio Pharmaceuticals, Inc.	02-07	CI
Fourth Motion for Exclusivity Period Extension Approved For PhaseBio Pharmaceuticals, Inc.	11-07	CI
PhaseBio Pharmaceuticals, Inc. Announces Resignation of Caroline Loewy as Member of the Board of Directors	23-10-03	CI
Third Motion for Exclusivity Period Extension Approved For PhaseBio Pharmaceuticals, Inc.	23-09-07	CI
Modified Combined Disclosure Statement Approved on Interim Basis for PhaseBio Pharmaceuticals, Inc.	23-08-01	CI
Second Motion for Exclusivity Period Extension Approved For PhaseBio Pharmaceuticals, Inc.	23-07-10	CI
Combined Liquidation Plan and Disclousre Statement Filed by PhaseBio Pharmaceuticals, Inc.	23-07-07	CI
North American Morning Briefing : Sentiment -2-	23-04-19	DJ
North American Morning Briefing : Traders Await -2-	23-04-12	DJ
North American Morning Briefing : Stock Futures -3-	23-04-05	DJ
First Motion for Exclusivity Period Extension Approved For PhaseBio Pharmaceuticals, Inc.	23-03-13	CI
First Motion for Exclusivity Period Extension Filed by PhaseBio Pharmaceuticals, Inc.	23-02-16	CI
Motion for Asset Sale Approved for PhaseBio Pharmaceuticals, Inc.	23-02-01	CI
Motion for Asset Sale Approved for PhaseBio Pharmaceuticals, Inc.	23-02-01	CI
Motion for De Minimis Assets Sale Approved for PhaseBio Pharmaceuticals, Inc.	23-01-30	CI
Notice of Selection of Auction and Asset Purchase Agreement Filed for Filed by PhaseBio Pharmaceuticals, Inc.	23-01-20	CI
Chiesi Farmaceutici S.p.A. cancelled the acquisition of all of the assets of PhaseBio Pharmaceuticals, Inc. primarily related to bentracimab.	23-01-18	CI
Notice of Rescheduled Auction Filed by PhaseBio Pharmaceuticals, Inc.	23-01-12	CI
Motion for Asset Sale Approved for PhaseBio Pharmaceuticals, Inc.	22-12-30	CI
Notice of Extention of Bidding Procedures Deadlines Filed by PhaseBio Pharmaceuticals, Inc.	22-12-22	CI
Notice of Rescheduled Auction Filed by PhaseBio Pharmaceuticals, Inc.	22-12-21	CI
PhaseBio Pharmaceuticals, Inc. Announces Executive Changes	22-12-02	CI
Bidding Procedure Approved for PhaseBio Pharmaceuticals, Inc.	22-11-27	CI

Chart PhaseBio Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel therapies for cardiovascular diseases. Its lead product candidate, bentracimab (also known as PB2452), is a novel reversal agent for the antiplatelet drug ticagrelor. Ticagrelor is an antiplatelet therapy widely prescribed to reduce the rates of death, heart attack and stroke in patients with acute coronary syndrome (ACS), or who have previously experienced a heart attack. Ticagrelor binds to platelets to prevent them from forming blood clots that could restrict blood flow. The Company is also developing its preclinical product candidate, PB6440, an oral selective aldosterone synthase inhibitor for treatment-resistant hypertension. The Company is leveraging ELP biopolymer technology to evaluate additional preclinical and discovery-stage candidates. Its focus is on proteins and peptides that are scientifically or clinically validated.

Sector

Biotechnology & Medical Research

More about the company

	1st Jan change	Capi.
PHASEBIO PHARMACEUTICALS, INC.	0.00%	49
VERTEX PHARMACEUTICALS INCORPORATED	+9.99%	115B
REGENERON PHARMACEUTICALS, INC.	+12.01%	106B
BIONTECH SE	-3.07%	24.69B
ARGENX SE	-0.12%	21.97B
GENMAB A/S	-4.64%	19.27B
BEIGENE, LTD.	-6.90%	17.56B
WUXI APPTEC CO., LTD.	-39.36%	17.32B
NEUROCRINE BIOSCIENCES, INC.	+5.82%	14.03B
SAREPTA THERAPEUTICS, INC.	+33.05%	12.13B

Bio Therapeutic Drugs